Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 18/20 | 1.00 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13595985 | 1.00 | CACNA1H (1.00) | CACNA1HNOS3NOS1NOS2LMNA | |
| SCHEMBL8223645 | 0.92 | CACNA1H (0.85) | CACNA1HLMNASMN1; SMN2 | |
| SCHEMBL13595895 | 0.91 | CACNA1H (0.84) | CACNA1H | |
| SCHEMBL8224684 | 0.91 | CACNA1H (1.00) | CACNA1HNOS3NOS1NOS2LMNA | |
| SCHEMBL13595860 | 0.91 | CACNA1H (0.83) | CACNA1HLMNASMN1; SMN2 | |
| SCHEMBL4104926 | 0.91 | CACNA1H (0.83) | CACNA1H | |
| SCHEMBL4104921 | 0.91 | CACNA1H (0.83) | CACNA1H | |
| SCHEMBL8223718 | 0.91 | CACNA1H (0.83) | CACNA1HLMNASMN1; SMN2 | |
| SCHEMBL13595891 | 0.89 | CACNA1H (0.81) | CACNA1HLMNASMN1; SMN2 | |
| SCHEMBL8224017 | 0.88 | CACNA1H (1.00) | CACNA1HNOS3NOS1NOS2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061462-A2 | TREATING PAIN, DIABETES AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080070892-A1 | TREATING PAIN, DIABETES, AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070892-A1 | TREATING PAIN, DIABETES, AND DISORDERS OF LIPID METABOLISM | PNLIP, LIPC, LIPE | CACNA1H 1761/4885NOS3 1332/4885NOS1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.